Parabilis Medicines closed a $305 million Series F round led by RA Capital, Fidelity and Janus Henderson to advance its Helicon peptide platform and lead candidate zolucatetide toward later‑stage trials. The financing increases the company’s runway to progress oncology programs that aim to reach intracellular or surface targets historically considered ‘undruggable.’ Parabilis said the candidate showed compelling early clinical data in its Phase 1/2 study; management flagged plans to push into registrational development and left the door open for a future IPO. The round follows renewed VC momentum in oncology platform companies and is among the largest disclosed fundraises in early January 2026. Investors cited Parabilis’ proprietary chemistry and early translational signals as the rationale for the oversubscribed financing.